

**Reference:** FOI.ICB-2324/023

**Subject:** Primary Care Rebates

*I can confirm that the ICB does hold the information requested; please see responses below:*

QUESTION	RESPONSE		
<p>Which primary care rebate schemes is your ICB/ Health Board currently signed to?</p> <p>If possible, could you please provide the start and end dates of these contracts.</p>	<b>Product brand name</b>	<b>Start date</b>	<b>End date</b>
	Adcal D3	01/04/2018	Until termination
	BD Viva	01/12/2021	31/12/2023
	Butec	01/04/2021	30/04/2024
	Buvidal	01/07/2021	31/12/2023
	Clenil	01/07/2022	30/06/2024
	Espranor	01/01/2022	31/12/2023
	Fostair NEXThaler	01/07/2022	30/06/2024
	Fostair pMDI	01/07/2022	30/06/2024
	FreeStyle Libre	01/09/2022	31/08/2023
	Gatalin XL	01/12/2022	30/11/2023
	Glucophage	01/07/2022	30/06/2024
	NovoRapid	01/08/2021	31/07/2023
	Onglyza	Roll on of pre-merge agreements	Until termination
	Pipexus	01/11/2019	Until termination
Prostap	01/12/2021	30/11/2025	
Ranexa	01/10/2022	30/09/2024	

	Stexerol	01/10/2018	Until termination
	Strivit	01/04/2021	31/03/2024
	Vizidor & Vizidor Duo	01/01/2022	31/12/2023
	Xaggitin	01/04/2018	Until termination
	Zacco	01/07/2022	30/09/2023
	Zaluron XL	01/04/2018	31/05/2023
	National procurement for direct acting oral anticoagulants (DOACs)	01/01/2022	31/03/2024

***The information provided in this response is accurate as of 11 May 2023 and has been approved for release by Dr Joanne Medhurst, Chief Medical Officer for NHS Bristol, North Somerset and South Gloucestershire ICB.***